Keay Nakae
Stock Analyst at Chardan Capital
(4.30)
# 363
Out of 5,163 analysts
233
Total ratings
45.53%
Success rate
19.57%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.20 | +376.19% | 14 | Mar 12, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 → $14 | $4.15 | +237.35% | 20 | Mar 11, 2026 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $17.92 | +112.05% | 16 | Mar 9, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $475 → $425 | $313.41 | +35.61% | 15 | Feb 13, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $2.45 | +104.08% | 6 | Feb 12, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $60.36 | +65.67% | 7 | Jan 29, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $7 → $15 | $12.80 | +17.19% | 5 | Jan 29, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.53 | +209.05% | 23 | Jan 8, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 → $80 | $55.05 | +45.32% | 23 | Jan 7, 2026 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Buy | $40 | $2.47 | +1,519.43% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $33.19 | +5.45% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $30 | $22.26 | +34.77% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.26 | +17.37% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.82 | +119.78% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $6.86 | +410.20% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $8.63 | -30.48% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $2.43 | +146.91% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.57 | +1,308.20% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $14.55 | -58.76% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $6.19 | +6,038.93% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $8.07 | +581.54% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $4.20 | +138.10% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $26.74 | +227.23% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $2.48 | +424.19% | 3 | Feb 9, 2021 |
Orchestra BioMed Holdings
Mar 12, 2026
Maintains: Buy
Price Target: $20
Current: $4.20
Upside: +376.19%
SAB Biotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $4.15
Upside: +237.35%
Dyne Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $38
Current: $17.92
Upside: +112.05%
Alnylam Pharmaceuticals
Feb 13, 2026
Maintains: Buy
Price Target: $475 → $425
Current: $313.41
Upside: +35.61%
iBio, Inc.
Feb 12, 2026
Maintains: Buy
Price Target: $5
Current: $2.45
Upside: +104.08%
Monopar Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $100
Current: $60.36
Upside: +65.67%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $12.80
Upside: +17.19%
Coya Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $14
Current: $4.53
Upside: +209.05%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $55.05
Upside: +45.32%
Reviva Pharmaceuticals Holdings
Jan 5, 2026
Maintains: Buy
Price Target: $40
Current: $2.47
Upside: +1,519.43%
Jan 5, 2026
Maintains: Buy
Price Target: $24 → $35
Current: $33.19
Upside: +5.45%
Jan 5, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $22.26
Upside: +34.77%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.26
Upside: +17.37%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $1.82
Upside: +119.78%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $6.86
Upside: +410.20%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $8.63
Upside: -30.48%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $2.43
Upside: +146.91%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.57
Upside: +1,308.20%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $14.55
Upside: -58.76%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $6.19
Upside: +6,038.93%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $8.07
Upside: +581.54%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $4.20
Upside: +138.10%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $26.74
Upside: +227.23%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $2.48
Upside: +424.19%